이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

enVVeno Medical 관리

관리 기준 확인 2/4

enVVeno Medical's CEO는 Robert Berman, Apr2018 에 임명되었습니다 의 임기는 6.17 년입니다. 총 연간 보상은 $ 1.87M, 26.7% 로 구성됩니다. 26.7% 급여 및 73.3% 보너스(회사 주식 및 옵션 포함). 는 $ 48.11K 가치에 해당하는 회사 주식의 0.077% 직접 소유합니다. 48.11K. 경영진과 이사회의 평균 재임 기간은 각각 6.1 년과 5.7 년입니다.

주요 정보

Robert Berman

최고 경영자

US$1.9m

총 보상

CEO 급여 비율	26.7%
CEO 임기	6.4yrs
CEO 소유권	0.08%
경영진 평균 재임 기간	5.4yrs
이사회 평균 재임 기간	5.9yrs

최근 관리 업데이트

Recent updates

Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

Jun 26

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Mar 07

CEO 보상 분석

Robert Berman 의 보수는 enVVeno Medical 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$21m
Mar 31 2024	n/a	n/a	-US$22m
Dec 31 2023	US$2m	US$500k	-US$24m
Sep 30 2023	n/a	n/a	-US$24m
Jun 30 2023	n/a	n/a	-US$25m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$466k	US$450k	-US$25m
Sep 30 2022	n/a	n/a	-US$27m
Jun 30 2022	n/a	n/a	-US$24m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$10m	US$400k	-US$17m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$1m	US$400k	-US$10m
Sep 30 2020	n/a	n/a	-US$7m
Jun 30 2020	n/a	n/a	-US$7m
Mar 31 2020	n/a	n/a	-US$7m
Dec 31 2019	US$415k	US$400k	-US$8m
Sep 30 2019	n/a	n/a	-US$7m
Jun 30 2019	n/a	n/a	-US$7m
Mar 31 2019	n/a	n/a	-US$13m
Dec 31 2018	US$906k	US$293k	-US$16m

보상 대 시장: Robert 의 총 보상 ($USD 1.87M )은 US 시장( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 Robert 의 보상이 증가했습니다.

CEO

Robert Berman (61 yo)

6.4yrs

테뉴어

US$1,870,884

보상

Mr. Robert A. Berman serves as Chief Executive Officer and Director of enVVeno Medical Corporation (formerly known as Hancock Jaffe Laboratories, Inc.) since April 2018. From September 2017 to March 2018,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Robert Berman	CEO & Director	6.4yrs	US$1.87m	0.077% $ 46.1k
Craig Glynn	CFO, Treasurer & Secretary	4.4yrs	US$527.29k	0% $ 0
Hamed Alavi	Senior VP & Chief Technology Officer	1.7yrs	US$669.19k	데이터 없음
Marc Glickman	Senior VP & Chief Medical Officer	8.3yrs	US$776.38k	0.012% $ 7.2k
Warren Hancock	Co-founder	37.7yrs	데이터 없음	데이터 없음
Sandy Prietto	Vice President of Marketing	less than a year	데이터 없음	데이터 없음
Benedict Broennimann	Chief Medical Officer of Outside of United States	6.3yrs	US$240.00k	데이터 없음
Andrew Cormack	Chief Commercial Officer	less than a year	데이터 없음	데이터 없음

5.4yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 관리: NVNO 의 관리팀은 노련하고 경험 (평균 재직 기간 6.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Robert Berman	CEO & Director	6.4yrs	US$1.87m	0.077% $ 46.1k
Robert Gray	Independent Director	5yrs	US$77.50k	0.057% $ 34.4k
Matthew Jenusaitis	Independent Director	5yrs	US$75.00k	0.052% $ 31.2k
Afksendyios Kalangos	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Francis Duhay	Independent Director	5.9yrs	US$70.00k	0.16% $ 94.1k
Steve Elias	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Antonios Gasparis	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Wade Dimitri	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Sanjay Shrivastava	Independent Director	5.9yrs	US$75.00k	0.029% $ 17.5k

5.9yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: NVNO 의 이사회는 경험(평균 재직 기간 5.7 년)으로 간주됩니다.

enVVeno Medical 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

enVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer

enVVeno Medical Corporation, Annual General Meeting, Dec 05, 2023

Envveno Medical Promotes Hamed Alavi to Senior Vice President and Chief Technology Officer

Insufficient new directors

enVVeno Medical Corporation, Annual General Meeting, Nov 30, 2022

Insufficient new directors

Recent updates

New minor risk - Share price stability

enVVeno Medical Corporation has filed a Follow-on Equity Offering.

No longer forecast to breakeven

Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

enVeno Medical Corporation Announces Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the VenoValve(R) Pivotal Trial

enVVeno Medical Corporation Announces New Interim Venous Ulcer Healing Data from the VenoValve®? Pivotal Trial to Be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting

enVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024

enVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

enVVeno Medical Corporation Announces the Presentation of Positive Topline Efficacy Data Showing Significant Clinical Improvement from the Savve U.S. Pivotal Trial for the Venovalve

New minor risk - Share price stability

Forecast to breakeven in 2026

enVVeno Medical Corporation Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium

enVVeno Medical Corporation, Annual General Meeting, Dec 05, 2023

New minor risk - Shareholder dilution

Price target decreased by 15% to US$20.40

enVVeno Medical Corporation Achieves Full Enrollment for VenoValve U.S. Pivotal Trial

Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

New major risk - Share price stability

Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study

New minor risk - Share price stability

Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

Envveno Medical Promotes Hamed Alavi to Senior Vice President and Chief Technology Officer

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Envveno Medical Corporation Presents Positive Long-Term, Three-Year Observational Data from A Cohort of Patients That Participated in the Previously Concluded Venovalve First-In-Human Clinical Tria

Insufficient new directors

enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study

enVVeno Medical Corporation, Annual General Meeting, Nov 30, 2022

Insufficient new directors

Insufficient new directors

enVVeno Medical: Unique Exposure To Venous Treatment Domain

We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

enVVeno Medical reports Q2 results

We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth

Price target decreased to US$24.00

No longer forecast to breakeven

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Hancock Jaffe Laboratories, Inc Begins Enrollment for the U.S. Pivotal Trial for the Venovalve, Potential Treatment for Deep Venous Chronic Venous Insufficiency

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Price target decreased to US$26.00

Forecast to breakeven in 2024

New 90-day low: US$7.37

Price target lowered to US$28.00

Hancock Jaffe Laboratories, Inc. has completed a Composite Units Offering in the amount of $35.999992 million.

Hancock Jaffe Laboratories, Inc. Appoints Craig Glynn Chief Financial Officer

Hancock Jaffe Laboratories finance chief sheds interim tag

Hancock Jaffe Receives Formal Notification from the Nasdaq Hearings Panel

Hancock Jaffe approves 1:25 reverse stock split

Hancock Jaffe Laboratories, Inc. announced delayed 10-Q filing

Hancock Jaffe Laboratories, Inc., Annual General Meeting, Dec 17, 2020

Hancock Jaffe Laboratories, Inc. (NasdaqCM:HJLI) entered into non-binding letter of intent to acquire Catheter Precision, Inc.

New 90-day high - US$0.56

New 90-day low - US$0.31

Hancock Jaffe Regains Compliance with Nasdaq Stockholder's Equity Rule

New 90-day low - US$0.31

Hancock Jaffe Laboratories, Inc. announced that it has received $1.556 million in funding

Hancock Jaffe Laboratories, Inc. has completed a Composite Units Offering in the amount of $4 million.

Hancock Jaffe Laboratories, Inc. announced that it expects to receive $1.556 million in funding

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령